Long-term safety of NT-501 implant for MacTel type 2
Part of Eyes & vision clinical trials.
This study checks the long-term safety and effectiveness of the NT-501 implant for people with MacTel type 2. It is for people who have already been in an earlier NT-501 study, whether they got the real implant or a sham procedure.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have already taken part in a clinical study for NT-501 (the implant for MacTel).
- If you had the real NT-501 implant in a Phase 3 study, you must still have at least one implant in your eye.
- If you had the real implant in an earlier Phase 1 or Phase 2 study, you must still have at least one implant.
- If you received a sham (placebo) procedure in a Phase 3 study, you can join a new group that will receive the real implant.
- Women who can get pregnant must use highly effective birth control (like an IUD, implant, or abstinence) if they are in the sham-to-implant group.
- You cannot have any serious eye problems (like glaucoma, diabetic retinopathy, or certain lens opacities) that would interfere with the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether taking a daily serine supplement can help slow vision loss in people with MacTel type 2, a condition that affects the retina. If you qualify, you'll take the supplement or a placebo and have regular eye check-ups.
This study tests a device that is surgically implanted in the eye of people with late-stage age-related macular degeneration (AMD). It also uses vision training with a telescope-like tool to see if the treatment can improve day-to-day vision.
This study evaluates the long-term safety and effectiveness of the study drug ALXN2220 in people with transthyretin amyloid cardiomyopathy. It is an extension of a previous trial, so if you completed the earlier study, you may be able to continue receiving the treatment and be monitored for a longer period.
This trial tests whether KB801 can help heal persistent corneal defects better than a placebo. It is for people with neurotrophic keratitis (a condition where the cornea loses sensation) that has not improved with standard care.
This study follows people who completed an earlier 2-year trial of OTX-TKI, a small implant placed in the eye to treat wet age-related macular degeneration (a condition causing vision loss). Researchers want to make sure the treatment remains safe over time.
This trial tests a new gene therapy drug (KH631) to see if it is safe and tolerated in people with neovascular age-related macular degeneration (nAMD). It may help your retina problems, but the early goal is mainly to learn about side effects and how the treatment behaves in the eye.
Hear when a new Macular Telangiectasia Type 2 (MacTel) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.